CAMP4 Therapeutics is developing programmable oligonucleotide therapeutics to regulate gene expression. Faulty gene expression underlies many human diseases with restoration of gene expression to normal levels being a path to treat them. CAMP4’s approach is to identify gene specific regulatory RNA targets for the tunable upregulation of genes. To target the RNAs, CAMP4 is designing RNA actuators - programmable antisense oligonucleotides - that can produce specific changes in protein expression. CAMP4 is designing RNA Actuators to treat diseases throughout the body. CAMP4’s initial focus is on diseases of the liver and central nervous system, but the technology has the potential to apply to every human tissue.

CAMP4 Therapeutics

Founded: 2016
Location: Cambridge, MA
Employee range: 11 - 50
Funding: $100M B Jul 2022; $45M A Jun 2021; $30M Jun 2018
Investors: Patient Square Capital, Gaingels, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group

Short description:

Drug notes:

Long description:

Jobs: